نتایج جستجو برای: peginterferon alfa

تعداد نتایج: 19203  

Journal: :Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2004
Emmet B Keeffe Douglas T Dieterich Steven-Huy B Han Ira M Jacobson Paul Martin Eugene R Schiff Hillel Tobias

Chronic HBV infection is an important public health problem worldwide and in the United States. A treatment algorithm for the management of this disease, published previously by a panel of U.S. hepatologists, has been revised on the basis of new developments in the understanding of the disorder, the availability of more sensitive molecular diagnostic tests, and the licensure of new therapies. I...

Journal: :hepatitis monthly 0
marwa khairy endemic medicine department and hepatology unit, faculty of medicine, cairo university, cairo, egypt rabab fouad endemic medicine department and hepatology unit, faculty of medicine, cairo university, cairo, egypt mahassen mabrouk endemic medicine department and hepatology unit, faculty of medicine, cairo university, cairo, egypt wafaa el-akel endemic medicine department and hepatology unit, faculty of medicine, cairo university, cairo, egypt abu bakr awad bioinformatic and statistic department, faculty of computer sciences, cairo university, cairo, egypt rabab salama endemic medicine department and hepatology unit, faculty of medicine, cairo university, cairo, egypt; endemic medicine and hepatology department, kasr el-aini faculty of medicine, cairo university, cairo, egypt. tel: +20-25262555, fax: +20-25326439

conclusions: absence of the c allele was significantly associated with failure of response. the presence of c allele was associated with a favorable outcome. afp is a strong baseline predictor of hcv treatment response. a decision tree model is useful for predicting the probability of response to therapy. patients and methods: the study included 263 chronic hcv egyptian patients receiving peg-i...

2006
H. J. FLINK H. W. Tilanus

Background: Treatment with interferon-alfa has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. Aim: To investigate the safety of peginterferon alfa-2b in 300 hepatitis B e antigen-positive patients with compensated liver disease. Methods: Patients were treated with peginterferon al...

Journal: :The New England journal of medicine 2005
Angelo Andriulli Alessandra Mangia

BACKGROUND Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ...

اخوندی میبدی, محسن, امیربیگی, محمدکاظم, سلمان روغنی, حسن, عزیزی, ریحانه,

Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...

2015
Izumi Sato Takuro Shimbo Yohei Kawasaki Naohiko Masaki

PURPOSE We aimed to compare the rates of sustained virologic response (SVR) achieved with peginterferon (PEG-IFN) alfa-2a and alfa-2b in combination with ribavinin (RBV) for chronic hepatitis C, using a large database of hepatitis cases to improve the generalizability of these results. METHODS We identified patients with chronic hepatitis C who were treated with PEG-IFN alfa-2a or alfa-2b and...

2013
Adrian Streinu-Cercel Anca Victorița Trifan Florin Alexandru Căruntu Ioan Sporea Liliana Simona Gheorghe Manuela Curescu Mihai Mircea Diculescu Mihai Voiculescu Oliviu Pascu Isabelle Lonjon-Domanec Andrew Martin Hill Sorin Rugină

Methods Patients were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36 weeks. Severe fibrosis/cirrhosis was defined by liver biopsy (Metavir F3-4 or Ishak 3-6) or noninvasive tests. Platelet count >90,000/cmm was required at entry. HCV RNA was evaluated at baseline and Weeks 4 and 12 of treatment. Virological response wa...

Journal: :Therapeutics and Clinical Risk Management 2006
Antonino Picciotto

Hepatitis C virus (HCV) management in the transplant setting is still an open issue. The therapeutic strategies being addressed include: (a) pre-transplant prophylaxis (to prevent the infection of the transplanted organ); (b) post-transplant prophylaxis (to reduce the possibility of developing acute hepatitis); (c) management once the chronic disease has already set in and stabilized. Combinati...

Journal: :The New England journal of medicine 2011
Ira M Jacobson John G McHutchison Geoffrey Dusheiko Adrian M Di Bisceglie K Rajender Reddy Natalie H Bzowej Patrick Marcellin Andrew J Muir Peter Ferenci Robert Flisiak Jacob George Mario Rizzetto Daniel Shouval Ricard Sola Ruben A Terg Eric M Yoshida Nathalie Adda Leif Bengtsson Abdul J Sankoh Tara L Kieffer Shelley George Robert S Kauffman Stefan Zeuzem

BACKGROUND In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. METHODS In this international, phase 3, randomized, double-blind, placebo-controlled trial,...

Journal: :Hepatology 2003
Eva Herrmann Jung-Hun Lee George Marinos Marlene Modi Stefan Zeuzem

A dynamic equilibrium between viral production and clearance characterizes untreated chronic hepatitis C viral infection. After initiating antiviral treatment, a typical multiphasic decay of viremia can be observed and analyzed using mathematical models. To elucidate the antiviral mechanism of ribavirin when used in combination with (pegylated) interferon alfa, we investigated kinetic parameter...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید